首页 > 市场调查报告书 > 製药

疫苗

市场调查报告书

商品编码

1419145

疫苗市场规模和预测、全球和地区份额、趋势和成长机会分析报告范围：按类型、技术、应用、给药途径、年龄、最终用户（和地理位置）

Vaccines Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Type, Technology, Application, Route of Administration, Age, End User,(and Geography)

出版日期: 2023年11月30日 | 出版商:

The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格

简介目录

疫苗市场预计将从2022年的1,352.8亿美元成长到2030年的2,163.0亿美元；预计 2022 年至 2030 年复合CAGR为 6.0%。传染病流行率上升以及 COVID-19 大流行期间疫苗使用量的增加是推动疫苗市场成长的几个因素。

疫苗是一种生物製剂，可提供针对特定传染病或恶性疾病的主动获得性免疫力。疫苗製剂通常含有与致病微生物相似的试剂，通常由微生物、毒素或其表面蛋白之一的弱化或灭活形式製成。疫苗可以是预防性的，也可以是治疗性的，可以提供免疫力。

市场机会

治疗性疫苗开发

传统疫苗刺激针对病毒和细菌等特定病原体的抗体和免疫蛋白质的产生。同样，治疗性疫苗会刺激免疫系统瞄准癌细胞并控制爱滋病毒等慢性感染的进展。此外，治疗性疫苗通常会刺激接受者的免疫系统以减缓或阻止慢性疾病进展或针对癌细胞。此外，用于治疗非传染性疾病的治疗性疫苗涵盖多种可能的製剂、抗原和作用机制。因此，治疗性疫苗的开发将为2022-2030年的预测期间提供利润丰厚的市场机会。

正在开发的治疗性疫苗的例子

适应症开发阶段

卵巢癌第一期

多发性骨髓瘤第一期

1 型糖尿病临床前

急性骨髓性白血病3

间皮瘤2

资料来源：TheInsight Partners 分析

市场洞察

传染病不断增加

根据康乃狄克州公共卫生部 2020 年报告，以下是康乃狄克州 2020 年记录的传染病。

2020 年康乃狄克州通报疾病通报病例

疾病总数

甲型肝炎 15

98 型流感

疟疾4

结核病 54

SARS-CoV-2 2,00,379

资料来源：TheInsight Partners 分析

此外，下表显示卫生防护中心报告2020年值得注意的传染病：

值得注意的传染病

疾病总数

SARS-CoV-2 8847

水痘 1987

社区相关的抗甲氧西林金黄色葡萄球菌感染 813

登革热 22

结核病 3656

资料来源：TheInsight Partners 分析

在所有传染病中，SARS-CoV-2 在 2020 年至 2022 年期间一直处于高位，而登革热、水痘、结核病等其他疫苗的使用率却较低。然而，由于全球病例不断增加，SARS-CoV-2 疫苗的使用率一直很高。根据 2021 年发布的英国公共卫生报告，英国 12 个月的 DTaP/IPV/Hib/HepB3 疫苗接种覆盖率增加了 0.1% 至 92.2%，轮状病毒疫苗接种率增加了 0.3% 至 90.6%。而MenB2较上年下降0.1%，占92.3%。此外，英国 NHS 报告显示，2022 年 12 月，所有成人护理院居民中共有 88.9 人接种了 COVID-19 加强剂疫苗。因此，传染病盛行率上升，疫苗接种需求很高，导致 2022-2030 年预测期内整体市场成长。

基于类型的见解

根据类型，疫苗市场分为减毒活疫苗、灭活疫苗、类毒素疫苗、次单位和结合疫苗等。减毒活疫苗细分市场在 2022 年占据最大的市场份额。减毒活疫苗是用于预防多种疾病的非常有效的疫苗，包括流感、水痘、麻疹、小儿麻痹和结核病。根据世界卫生组织 (WHO) 的报告，全球约有 10 亿例季节性流感病例，其中 500 万例重症病例。此外，它每年导致约 29 万至 65 万人因呼吸系统死亡。因此，减毒活流感疫苗（LAIV）被证明有利于对抗人群中的感染。例如，LAIV 可为 65 岁以下的成年人提供高达 90% 的保护，为 65 岁以上的成年人提供高达 40% 的保护。上述因素对 2022-2030 年预测期间的细分市场成长有影响。

根据应用，疫苗市场分为人类乳突病毒 (HPV)、癌症、MMR、DPT 等。 2022 年，HPV 细分市场占据最大的市场份额。根据WHO 报告，HPV 在撒哈拉以南非洲地区的女性中高度流行（24%），其次是拉丁美洲和加勒比地区（16%）、东欧（14% ））和东南亚（14%）。此外，全球每年有 625,600 名女性和 694,000 名男性患有 HPV 相关癌症。此外，到 2020 年，子宫颈癌占女性 HPV 相关癌症的 93%。因此，由于盛行率上升，人们对 HPV 疫苗的需求很高，因为这些疫苗可以预防尖圭湿疣和大多数子宫颈癌。此外，HPV疫苗得到了美国食品药物管理局（USFDA）的高度认可。「GARDASIL 9」就是美国 FDA 核准的 HPV 疫苗的一个例子。上述因素对 2022-2030 年预测期间的细分市场成长具有影响力。

基于管理的洞察之路

从给药途径来看，疫苗市场分为口服、鼻腔和注射。注射剂细分市场在 2022 年将占据更大的市场份额。最常见的疫苗接种途径是注射途径，因为透过皮下或皮内途径注射疫苗可能会导致局部刺激、皮肤变色、发炎等。

此外，CDC 报告显示 DTaP、DT、HepA、HepB、Hib、HPV、IIV4、RIV4、ccIIV4、IPV*†、MenACWY、MenB、MMR‡、PCV13、PPSV23*†、RZV、Td、Tdap、TT、 VAR†是经由注射给药途径施用的常见疫苗。透过注射途径注射的各种疫苗是影响 2022-2030 年预测期间细分市场成长的独立因素。

欧洲
- 德国
- 法国
- 义大利
- 西班牙
- 英国
- 欧洲其他地区
亚太
- 澳洲
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区
南美洲和中美洲
- 巴西
- 阿根廷
- 南美洲和中美洲其他地区

第 14 章：Covid-19 前后的影响

第 15 章：产业格局

併购
协议、合作、合资企业
新产品发布
扩张和其他策略发展

第16章：竞争格局

关键参与者的热图分析
公司定位与专注

第 17 章：疫苗市场 - 主要公司概况

注意 - 将为以下公司列表提供类似信息

辉瑞公司
赛诺菲
默克
印度血清研究所 (SII)
阿斯利康
生物科技
生物E
科兴
国药控股
巴拉特生物技术公司

第 18 章：附录

词彙表
关于 Insight Partners
市场情报云

简介目录

Product Code: TIPRE00015468

The vaccines market is expected to grow from US$ 135.28 billion in 2022 to US$ 216.30 billion by 2030; it is expected to grow at a CAGR of 6.0% from 2022 to 2030. Rising prevalence of infectious diseases and an increase for uptake of vaccines amid the COVID-19 pandemic are a few factors driving the vaccines market growth.

A vaccine is a biological preparation that provides active acquired immunity to a particular infectious or malignant disease. A vaccine typically preparation contains an agent responsible for resembling a disease-causing microorganism and is often made from a weakened or killed form of the microbe, toxin, or one of its surface proteins. Vaccines can be prophylactic or therapeutic, offering immunity.

Market Opportunity

Therapeutic Vaccine Development

Traditional vaccines stimulate the production of antibodies and immune proteins that target specific pathogens like viruses and bacteria. Likewise, therapeutic vaccines stimulate the immune system to target cancer cells and control the progression of chronic infections like HIV. Further, therapeutic vaccines typically stimulate the recipient's immune system to slow or stop chronic disease progression or target cancer cells. Further, therapeutic vaccines for the treatment of noninfectious diseases encompass a wide variety of possible formulations, antigens, and mechanism of action. Therefore, therapeutic vaccines development will provide lucrative market opportunity for the forecast period 2022-2030.

Examples of Therapeutic Vaccines in Development

Indication Development Phase

Ovarian Cancer Phase 1

Multiple Myeloma Phase 1

Type 1 Diabetes Preclinical

Acute Myelogenous Leukemia 3

Mesothelioma 2

Source: TheInsight Partners Analysis

Market Insights

Rising Infectious Diseases

According to the Connecticut Department of Public Health report 2020, below are the infectious diseases recorded in 2020 in Connecticut.

Reported Cases of Connecticut Reportable Diseases in 2020

Disease Total

Hepatitis A 15

Influenza 98

Malaria 4

Tuberculosis 54

SARS-CoV-2 2,00,379

Source: TheInsight Partners Analysis

Additionally, the below table reveals notable infectious disease by the Center for Health Protection report in 2020:

Notable Infectious Disease

Disease Total

SARS-CoV-2 8847

Chickenpox 1987

Community-associated methicillin-resistant Staphylococcus aureus infection 813

Dengue Fever 22

Tuberculosis 3656

Source: TheInsight Partners Analysis

Among all the infectious diseases, SARS-CoV-2 was all time high during 2020 to 2022 period where other uptake of vaccines including Dengue, Chickenpox, Tuberculosis, and others were low. However, SARS-CoV-2 vaccines uptake was all time high due to rising cases globally. According to the Public Health England report published in 2021, 12-month UK coverage for DTaP/IPV/Hib/HepB3 vaccination increased by 0.1% to 92.2% and Rotavirus by 0.3% to 90.6%. However, MenB2 decreased by 0.1, accounting for 92.3% compared to the previous year. Also, the NHS England report reveals that, in December 2022, a total of 88.9 of all adult care home residents had been vaccinated with a COVID-19 booster dose. Therefore, rising prevalence of infectious diseases, demand for vaccination is high resulting in overall market growth for the forecast period 2022-2030.

Type-Based Insights

Based on type, the vaccines market is segmented as live attenuated vaccines, inactivated vaccines, toxoid vaccines, subunit & conjugate vaccines, and others. The live attenuated vaccines segment held the largest market share in 2022. Live attenuated vaccines are very effective vaccines used in the prevention of a variety of diseases, including influenza, chickenpox, measles, polio, and tuberculosis. As per the World Health Organization (WHO) report, there are around a billion cases of seasonal influenza, including 5 million cases of severe illness. Also, it causes around 290,000 to 650,000 respiratory deaths annually. Therefore, live-attenuated influenza vaccine (LAIV) proves advantageous to combat the infection among the population. For example, LAIV can provide upto 90% protection among adults under 65 years of age and upto 40% of adults over 65. The aforementioned factors are responsible for influential segment growth for the forecast period 2022-2030.

Based on application, the vaccines market is segregated into Human Papillomavirus (HPV), cancer, MMR, DPT, and others. The HPV segment held the largest market share in 2022. According to the WHO report, HPV is highly prevalent among women in Sub-Saharan Africa (24%), followed by Latin America and the Caribbean (16%), Eastern Europe (14%), and South-East Asia (14%). Also, 625,600 women and 694,000 men have HPV-related cancer annually globally. Also, in 2020, cervical cancer accounted for 93% of HPV-related cancers among women. Therefore, there is a high demand for HPV vaccines among the population due to rising prevalent cases, as these vaccines protect against genital warts and most cases of cervical cancer. Also, HPV vaccines are highly approved by the US Food and Drug Administration (USFDA). "GARDASIL 9" is one such example of an HPV vaccine approved by the US FDA. The aforementioned factors are responsible for influential segment growth for the forecast period 2022-2030.

Route of Administration-Based Insights

In terms of route of administration, the vaccines market is categorized as oral, nasal, and injectable. The injectable segment held a larger share of the market in 2022. The most common route of vaccine administration is through the injectable route, as administering a vaccine through a subcutaneous or intradermal route may cause local irritation, skin discoloration, inflammation, and many more.

Further, the CDC report reveals that DTaP, DT, HepA, HepB, Hib, HPV, IIV4, RIV4, ccIIV4, IPV*†, MenACWY, MenB, MMR‡ , PCV13, PPSV23*†, RZV, Td, Tdap, TT, VAR† are common vaccines administered through the injectable route of administration. Varied vaccines administered through injectable routes act as a standalone factor responsible for influential segment growth for the forecast period 2022-2030.

1. Introduction

1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness Analysis

3. Research Methodology

4. Vaccines Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain

5. Vaccines Market - Key Market Dynamics

5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints

6. Vaccines Market - Global Market Analysis

6.1 Vaccines - Global Market Overview
6.2 Vaccines - Global Market and Forecast to 2030

7. Vaccines Market - Revenue Analysis (USD Million) - By Type, 2020-2030

7.1 Overview
7.2 Live Attenuated Vaccines
7.3 Inactivated Vaccines
7.4 Toxoid Vaccines
7.5 Subunit and Conjugate Vaccines
7.6 Others

8. Vaccines Market - Revenue Analysis (USD Million) - By Technology, 2020-2030

8.1 Overview
8.2 Recombinant Vaccines
8.3 mRNA Vaccines
8.4 Cell-Based Vaccines
8.5 Virus-Like Particles (VLPs)
8.6 Others

9. Vaccines Market - Revenue Analysis (USD Million) - By Application, 2020-2030

9.1 Overview
9.2 Human Papillomavirus (HPV)
9.3 Cancer
9.4 Measles, Mumps, Rubella (MMR)
9.5 Diptheria, Pertusis, Tetanus (DPT)
9.6 Others

10. Vaccines Market - Revenue Analysis (USD Million) - By Route of Administration, 2020-2030

10.1 Overview
10.2 Oral
10.3 Injectable
10.4 Nasal

11. Vaccines Market - Revenue Analysis (USD Million) - By Age, 2020-2030

11.1 Overview
11.2 Pediatric
11.3 Adult

12. Vaccines Market - Revenue Analysis (USD Million) - By End User, 2020-2030

12.1 Overview
12.2 Healthcare Facilities (HCF)
12.3 Vaccination Centers and Programs
12.4 Others

13. Vaccines Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

13.1 North America
- 13.1.1 North America Vaccines Market Overview
- 13.1.2 North America Vaccines Market Revenue and Forecasts to 2030
- 13.1.3 North America Vaccines Market Revenue and Forecasts and Analysis - By Type
- 13.1.4 North America Vaccines Market Revenue and Forecasts and Analysis - By Technology
- 13.1.5 North America Vaccines Market Revenue and Forecasts and Analysis - By Application
- 13.1.6 North America Vaccines Market Revenue and Forecasts and Analysis - By Route of Administration
- 13.1.7 North America Vaccines Market Revenue and Forecasts and Analysis - By Age
- 13.1.8 North America Vaccines Market Revenue and Forecasts and Analysis - By End User
- 13.1.9 North America Vaccines Market Revenue and Forecasts and Analysis - By Countries
  - 13.1.9.1 United States Vaccines Market
    - 13.1.9.1.1 United States Vaccines Market, by Type
    - 13.1.9.1.2 United States Vaccines Market, by Technology
    - 13.1.9.1.3 United States Vaccines Market, by Application
    - 13.1.9.1.4 United States Vaccines Market, by Route of Administration
    - 13.1.9.1.5 United States Vaccines Market, by Age
    - 13.1.9.1.6 United States Vaccines Market, by End User
  - 13.1.9.2 Canada Vaccines Market
    - 13.1.9.2.1 Canada Vaccines Market, by Type
    - 13.1.9.2.2 Canada Vaccines Market, by Technology
    - 13.1.9.2.3 Canada Vaccines Market, by Application
    - 13.1.9.2.4 Canada Vaccines Market, by Route of Administration
    - 13.1.9.2.5 Canada Vaccines Market, by Age
    - 13.1.9.2.6 Canada Vaccines Market, by End User
  - 13.1.9.3 Mexico Vaccines Market
    - 13.1.9.3.1 Mexico Vaccines Market, by Type
    - 13.1.9.3.2 Mexico Vaccines Market, by Technology
    - 13.1.9.3.3 Mexico Vaccines Market, by Application
    - 13.1.9.3.4 Mexico Vaccines Market, by Route of Administration
    - 13.1.9.3.5 Mexico Vaccines Market, by Age
    - 13.1.9.3.6 Mexico Vaccines Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

13.2 Europe
- 13.2.1 Germany
- 13.2.2 France
- 13.2.3 Italy
- 13.2.4 Spain
- 13.2.5 United Kingdom
- 13.2.6 Rest of Europe
13.3 Asia-Pacific
- 13.3.1 Australia
- 13.3.2 China
- 13.3.3 India
- 13.3.4 Japan
- 13.3.5 South Korea
- 13.3.6 Rest of Asia-Pacific
13.4 Middle East and Africa
- 13.4.1 South Africa
- 13.4.2 Saudi Arabia
- 13.4.3 U.A.E
- 13.4.4 Rest of Middle East and Africa
13.5 South and Central America
- 13.5.1 Brazil
- 13.5.2 Argentina
- 13.5.3 Rest of South and Central America

14. Pre and Post Covid-19 Impact

15. Industry Landscape

15.1 Mergers and Acquisitions
15.2 Agreements, Collaborations, Joint Ventures
15.3 New Product Launches
15.4 Expansions and Other Strategic Developments

16. Competitive Landscape

16.1 Heat Map Analysis by Key Players
16.2 Company Positioning and Concentration

17. Vaccines Market - Key Company Profiles

17.1 GSK
- 17.1.1 Key Facts
- 17.1.2 Business Description
- 17.1.3 Products and Services
- 17.1.4 Financial Overview
- 17.1.5 SWOT Analysis
- 17.1.6 Key Developments

Note - Similar information would be provided for below list of companies